2020 Revenues ($USD) : $2,363,567,000
2020 R&D spend : $335,375,000
2020 Number of Employees : 1,940
Fiscal Year End : 12/31/2020
Key People : Bruce C. Cozadd, CEO
Jazz Pharma facility in Dublin, Ireland
Jazz Pharmaceuticals is a global biopharmaceutical company developing medicines for people with serious diseases with limited or no options. Its treatments focus on neurosciences therapeutics and hematology and oncology. The Dublin, Ireland–based company has seven commercialized drugs. They include Xyrem and Xywav for treating cataplexy and EDS in adult and pediatric patients with narcolepsy; Sunosi for improving wakefulness in adult patients with EDS associated with narcolepsy or OSA; Defitelio for treating VOD; Erwinaze for patients who have developed hypersensitivity to E. coli-derived asparaginase while undergoing chemotherapy; Vyxeosfor treating adults with newly-diagnosed t-AML or AML-MRC and Zepzelca for treating adults with metastatic small lung cancer. Jazz Pharmaceuticals recently won FDA approval for its Vyxeos drug for treating secondary acute myeloid leukemia in pediatric patients. Company officials expect to acquire GW Pharmaceuticals for $7.2 billion, or $6.7 billion net of GW cash, later this year. –DK